Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03727802) tested a medicine called TRK-250 across two parts (Part A and Part B). In Part A, small groups of three to four participants each received one of four different doses of TRK-250 (2 mg, 10 mg, 30 mg, or 60 mg), while four participants received a placebo (a dummy treatment with no active ingredient). In Part B, groups of four participants received one of three doses of TRK-250 (10 mg, 30 mg, or 60 mg), and six participants received a placebo. In total, 34 people started the trial, and 32 completed it — one person in the Part B 60 mg group and one in the Part B placebo group did not finish. The primary outcome — meaning the main thing the trial set out to measure — was the number of participants who experienced adverse events (unwanted or unexpected health occurrences) and how severe those were. The reported data shows that in Part A, 1 participant in the 2 mg group, 0 in the 10 mg group, 3 in the 30 mg group, 2 in the 60 mg group, and 1 in the placebo group reported adverse events. In Part B, 3 participants in the 10 mg group, 2 in the 30 mg group, 3 in the 60 mg group, and 3 in the placebo group reported adverse events. Some severity-level figures were partially reported (for example, 2 participants in the Part A 30 mg group were noted at a particular severity level), but the remaining severity breakdown data was not fully reported in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37738329) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 1 Interstitial Lung Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with IPF (idiopathic pulmonary fibrosis) based on clinical assessment, imaging, and tissue analysis.
- Your blood oxygen level is 90% or higher when measured at rest while breathing normal air.
- Your lung capacity (the amount of air you can breathe in) is at least 50% of what is expected for someone of your age and size.
- The amount of air you can forcefully breathe out in one second is at least 50% of what is expected for someone of your age and size.
- The ratio of air breathed out quickly to your total lung capacity meets a certain threshold (confirm with trial site).
- Your lungs' ability to transfer oxygen into the blood falls within a specific range — between 30% and 79% of the expected level.
Who may not be able to join:
- You have had a sudden worsening of your IPF or a respiratory infection in the past 3 months.
- You have surgery planned during the period of the study.
- You have been diagnosed with cancer within the past 5 years.
- You have emphysema or another significant lung or breathing condition besides IPF.
- Your lung disease is known to be caused by something other than IPF, such as a medication, environmental exposure, or another illness affecting the immune system.
- Your lung disease is so advanced that doctors expect you may need a lung transplant within the next 6 months.
- You have taken certain medications — including steroids, chemotherapy-type drugs, or treatments for high blood pressure in the lungs — within the past 4 weeks (note: the IPF medications pirfenidone or nintedanib may be allowed if you have been on a stable dose for at least 4 weeks and the dose is not expected to change — confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and Severity of Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.